ASXL1 and myeloproliferative disorder: Within the group of de novo AML and intermediate risk karyotype, excluding patients with previous MDS or MDS/MPN, median survival of ASXL1+ was 100 days 95% CI (38‐162, N = 5) and of ASXL1− was 363 days 95% CI (222‐504, N = 12), P = .061, which represent a hazard ratio of ASXL1 mutation of 2.9 95% CI (0.9‐9.2), P = .072 (Figure 3B).